Research shows innovative approach serves health care consumers over long term.
Dr. Diana Buist explains the new Breast Cancer Surveillance Consortium study in JAMA Oncology, which she co-wrote.
Based on a new BCSC study, Dr. Diana Buist tells of technology that adds cost to breast cancer screening—without improving outcomes. Dr. Marc Mora comments.
CAD raises screening costs without benefit to patients and may miss cancers, large national BCSC study shows.
Study identifies substantial over- and underuse of lipid testing.
A Breast Cancer Surveillance Consortium study involving Group Health shows that density shouldn’t be the only factor when considering additional screening.
With Kaiser Permanente colleagues, Group Health finds cost savings for two years.
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.